Glioblastoma (GBM) is the most common aggressive primary malignant brain tumorin adults with a median age of onset of 65 years of age. Although advanced age is often associated with worse GBM patient survival, the predominant source(s) of maladaptive aging
effects remains to be established. Here we studied intra-tumoral and...
Glioblastoma (GBM) is a highly malignant brain tumor that accounts for the most commonly diagnosed type of primary brain tumors in adults. It has a poor prognosis of only 15 months from the time of diagnosis. The gold standard therapy regimen consists of radiotherapy and the chemotherapeutic temozolomide. Both of...
Glioblastoma multiforme (GBM) is the most prevalent primary central nervous system tumor, characterized by resistance to therapeutic intervention, inevitable recurrence, and ultimately patient death. The dismal prognosis is due in part to underlying molecular factors that promote an intratumoral cellular state heterogeneity and protect tumor cells from cell death pathways....
Background: Glioblastoma (GBM) tumors are the most malignant brain cancers and are characterized as Grade IV astrocytomas by the World Health Organization. GBM tumors can be classified into three molecular subtypes known as proneural, classical, and mesenchymal. In addition, GBM tumors also have a small population of cells known as...
Astrocytes are the most abundant cell type in the brain, yet the mechanisms involved in astrocyte differentiation and the level of astrocyte heterogeneity in the CNS, particularly in the human cortex, is largely unknown due to the lack of subtype-specific astrocyte markers and inaccessibility of human brain tissue. Here we...
Biologically active small molecules remain the foundation for the medical management of human disease. Their impacts on human health, longevity, culture, and society are difficultly overstated. In large part, medicines derived from organic compounds are the result of the tireless efforts of chemical practitioners––both past and present––who have dedicated much...
Multiple facets of the natural trajectory of glioma remain poorly understood, which results in a universally poor prognosis for patients with glioma. Many patients with glioma experience tumor-associated epilepsy (TAE) throughout their disease course, but the mechanism by which TAE occurs, who is at continued risk for TAE, and whether...
Glioblastoma multiforme (GBM) is the most prevalent primary central nervous system malignancy. Due to the aggressive nature of these tumors and our inability to adequately treat them, only 3-5% of patients survive longer than 3 years post-diagnosis. The standard of care for newly diagnosed GBM is surgical resection followed by...
MAPK-interacting kinase (MNK) signaling leads to activation of cap-dependent mRNA translation through phosphorylation of the eukaryotic translation initiation factor 4E (eIF4E). In cancer cells, MNK-eIF4E signaling promotes translation of oncogenic mRNAs. In glioblastoma (GBM), the deadliest malignant brain tumor, MNK-eIF4E signaling is aberrantly activated and represents a promising therapeutic target....